Free Trial
CVE:MPH

Medicure (MPH) Stock Price, News & Analysis

Medicure logo
C$0.89 -0.01 (-1.11%)
(As of 12/23/2024 05:32 PM ET)

About Medicure Stock (CVE:MPH)

Key Stats

Today's Range
C$0.89
C$0.89
50-Day Range
C$0.88
C$1.08
52-Week Range
C$0.84
C$1.45
Volume
2,000 shs
Average Volume
4,561 shs
Market Capitalization
C$9.29 million
P/E Ratio
N/A
Dividend Yield
2.24%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Receive MPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicure and its competitors with MarketBeat's FREE daily newsletter.

MPH Stock News Headlines

Medicure Inc. (NGQ1.F)
We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Medicure Inc. (MPH.V)
MPH:CA Medicure Inc.
See More Headlines

MPH Stock Analysis - Frequently Asked Questions

Medicure's stock was trading at C$1.40 at the start of the year. Since then, MPH shares have decreased by 36.4% and is now trading at C$0.89.
View the best growth stocks for 2024 here
.

Medicure Inc. (CVE:MPH) issued its quarterly earnings data on Wednesday, May, 24th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of $0.04 by $0.37. The firm earned $8.71 million during the quarter, compared to the consensus estimate of $14.50 million. Medicure had a negative net margin of 12.56% and a negative trailing twelve-month return on equity of 12.90%.

Shares of MPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicure investors own include Dollarama (DOL), Alimentation Couche-Tard (ATD.B), Canoe EIT Income Fund (ENDTF), Allena Pharmaceuticals (ALNA), Hudbay Minerals (HBM), ProMetic Life Sciences (PLI) and Athersys (ATHX).

Company Calendar

Last Earnings
5/24/2017
Today
12/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
C$-2,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$20.93 million
Cash Flow
C$0.36 per share
Book Value
C$1.87 per share

Miscellaneous

Free Float
N/A
Market Cap
C$9.29 million
Optionable
Not Optionable
Beta
0.90
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (CVE:MPH) was last updated on 12/26/2024 by MarketBeat.com Staff
From Our Partners